Compare Keel Infrastructure Corp. Common Stock (KEEL) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keel Infrastructure Corp. Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? Keel Infrastructure Corp. Common Stock trades at $2.48 (market cap $1.77B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 4.2× Keel Infrastructure Corp. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Keel Infrastructure Corp. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Keel Infrastructure Corp. Common Stock for 3 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| KEEL | SYRE | |
|---|---|---|
Market Cap | $1.77B | $7.52B |
Volume | 34,111,650 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $6.66 | $108.92 |
52-Week Low | $1.71 | $22.18 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $2.09B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KEEL trades at $2.87, down 2.71% on the day, reflecting a bearish technical trend amid weak financial performance. The company reported a net loss of $208.51M on $229.28M revenue in 2025, with negative profit margins and cash flow from operations. Despite this, analyst consensus is unanimously bullish with a $6.25 price target, citing progress in its HPC and AI data center strategy, including a recent partnership with PowerSecure for its Moses Lake campus.
The outlook hinges on successful execution of its data center pivot, offering significant upside if leasing targets are met, but high execution risk and persistent losses pose substantial threats to shareholder value. Liquidity remains supported by financing activities, yet profitability challenges and competitive pressures require careful monitoring.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Keel Infrastructure Corp. Common Stock
Keel Infrastructure develops and owns digital and energy infrastructure for high-performance computing workloads. Its assets include data centers and power infrastructure that support AI computing.
Read more on KEEL →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
